GlassScriptPhysician profile
Jennifer Ahmed
NPI 1619139201
$47,361.42
in general payments reported to CMS, 2019-2025
63 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $540 · 2021: $2,232 · 2022: $2,792 · 2023: $8,127 · 2024: $9,868 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $10K · Travel and Lodging: $1,030 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,137.50 |
| Food and Beverage | $10,462.90 |
| Travel and Lodging | $1,030.04 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35,436.56 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $1,083.65 | 2021-2025 | |
| Lundbeck LLC | $1,039.63 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $1,006.54 | 2019-2025 | |
| Allergan, INC. | $911.59 | 2019-2022 | |
| Emd Serono, INC. | $773.49 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $514.06 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Argenx US, INC. | $511.15 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $426.97 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $344.37 | 2019-2025 | Austedo Xr |
| Amgen INC. | $318.05 | 2021-2025 | Uplizna, Aimovig |
| Harmony Biosciences LLC | $299.27 | 2022-2025 | Wakix |
| Alexion Pharmaceuticals, INC. | $284.23 | 2019-2025 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $261.40 | 2022-2025 | Crexont, Rytary |
| Biohaven Pharmaceuticals, INC. | $224.46 | 2021 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.